Navigation Links
Onconase in Medical News

Alfacell Announces Management Update

... rolling New Drug Application (NDA) submission for onconase in patients suffering from unresectable malignant ...eeting at the end of January 2009. About onconase (R) onconase is a first-in-class therapeutic product candidate ...

Alfacell Reports Financial Results for First Quarter of Fiscal 2009

...leted a confirmatory Phase IIIb clinical trial for onconase in patients suffering from unresectable malignant ...etails of the planned NDA submission. About onconase (R) onconase is a first-in-class therapeutic product candidate ...

Alfacell to Host Fiscal First Quarter 2008 Financial Results Conference Call and Webcast

...nd other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of onconase in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com . Safe Harbor This press releas...
Onconase in Medical Technology

Alfacell's Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies

BLOOMFIELD, N.J., March 20, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation's ONCONASE (ranpirnase) has shown potential to act as a potent payload in antibody conjugates for cancer therapy, according to the latest edition of the Handbook of Therapeutic Antibodies. In a chapter of the text th...

Preclinical Data Show Alfacell's Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells

Poster Presented at AACR Annual Meeting BLOOMFIELD, N.J., April 16, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that in vivo and in vitro preclinical data presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting show that ONCONASE (ranpirn...

Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacell's Onconase

BLOOMFIELD, N.J., March 22, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today reported that in vitro studies show mild hyperthermia enhances the therapeutic effects of ONCONASE (ranpirnase), the company's lead investigational drug candidate. In a paper entitled, "Mild hyperthermia predis...

Researchers Identify Intracellular Pathway of Alfacell's Onconase

Paper Published in Journal of Cell Science Shows ONCONASE Uptake in Cells Differs from other RNases BLOOMFIELD, N.J., April 05, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that European researchers have identified the pathway that ONCONASE (ranpirnase) follows to enter cell...

Alfacell Provides Shareholder Update

...ofile, its ability to overcome MDR, I believe that onconase remains a viable candidate for second line therapy in MM. The fact that onconase was able to extend the lives of patients who had f...tudies on immune deficient mice to see what effect onconase would have on human tumors grafted onto these mice...

Alfacell Provides ONCONASE(R) NDA Submission Update

... planned submission of the final components of the onconase rolling New Drug Application (NDA) for the treatme... planned submission of the final components of the onconase rolling NDA for patients that have failed prior ch...y. Therefore, the final components of the rolling onconase NDA will not be finalized until Alfacell receives ...

Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines

...py. The study demonstrated that the combination of onconase and rosiglitazone synergistically decreased cell v... The study concludes the novel drug combination of onconase and rosiglitazone is a promising combination. "T... in vivo studies and demonstrates the potential of onconase for effective use in cancer treatments via multipl...

Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel

...product in our oncology portfolio. We believe that onconase will prove to be a promising new treatment option ...with an ideal partner to maximize the potential of onconase in this region. We look forward to a successful co...llaboration with Megapharm." About ONCONASE(R) onconase is a first-in-class therapeutic product candidate ...

Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial

...ry Phase IIIb clinical trial of its lead compound, onconase (ranpirnase), did not meet statistical significanc...MM patients who were treated with a combination of onconase plus doxorubicin as compared to patients who were ...val time (MST) for evaluable patients who received onconase plus doxorubicin was 11.1 months as compared to 10...

Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial

...MM patients who were treated with a combination of onconase plus doxorubicin as compared to patients who were ...val time (MST) for evaluable patients who received onconase plus doxorubicin was 11.1 months as compared to 10...ntering this clinical trial. Patients who received onconase plus doxorubicin experienced a MST of 10.5 months ...

More>>

Onconase in Biological Technology

Alfacell Provides ONCONASE(R) NDA Submission Update

... planned submission of the final components of the onconase rolling New Drug Application (NDA) for the treatme...rom the confirmatory Phase IIIb clinical trial for onconase in patients suffering from UMM did not meet statis...ation effective as of January 1, 2009. About onconase (R) ...

Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells

...ct 4205 & 2008 112: Abstract 4010) report that onconase (ranpirnase) and R-Amphinase (R-Amph) show anti-tu...tment of Pathology at New York Medical College . onconase and R-Amph are amphibian endoribonucleases with un...ammed cell death) of malignant cells. Previously, onconase has been shown to affect multiple cellular pathway...

Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results

...nt in a confirmatory Phase IIIb clinical trial for onconase in patients suffering from unresectable malignant ...ses required to complete the final sections of the onconase rolling NDA. As the company has previously reporte...nd completion of the Phase IIIb clinical trial for onconase in UMM. In fiscal 2009, we plan to complete the ND...

Paper in Cell Cycle Reports Alfacell's ONCONASE(R) Targets siRNA

...n Cell Cycle (2008; Vol. 7, Issue 20) reports that onconase (ranpirnase) targets small interfering RNA (siRNA)...he expression was restored in the cells exposed to onconase for 48 or 72 hours. The data thus provide evidence...his data provide further evidence of the impact of onconase on the RNAi mechanism," said Kuslima Shogen, Alfac...

Alfacell Hires Advisors to Advance Strategic Alternatives

...oved a specific transaction. About ONCONASE(R) onconase is a first-in-class therapeutic product candidate ... A natural protein isolated from the leopard frog, onconase has been shown in the laboratory and clinic to tar...facell has licensed the U.S. commercial rights for onconase to Strativa Pharmaceuticals, a division of Par Pha...

Alfacell Receives NASDAQ Delisting Letter

...e development of a new class of targeted therapies for cancer and other life-threatening diseases. Alfacell has completed Phase III clinical trials of onconase in unresectable malignant mesothelioma and, in addition to ongoing efforts to complete the related rolling New Drug Application, Alfacell is currently...

Alfacell Receives NASDAQ Non-Compliance Notification

...e development of a new class of targeted therapies for cancer and other life-threatening diseases. Alfacell has completed Phase III clinical trials of onconase in unresectable malignant mesothelioma and, in addition to ongoing efforts to complete the related rolling New Drug Application, Alfacell is currently...

Alfacell Reports Financial Results for Third Quarter of Fiscal 2008

...ent expectations for the planned completion of the onconase rolling NDA. The company will be eligible to recei...nt in a confirmatory Phase IIIb clinical trial for onconase in patients suffering from unresectable malignant ...ses required to complete the final sections of the onconase rolling NDA. As the company has previously reporte...

Alfacell Announces Retirement of Chief Executive Officer

...us upon receiving marketing approval by the FDA of onconase for the treatment of malignant mesothelioma, a sig...lfacell in the event aggregate annual net sales of onconase exceed $100 million. "Tina's contributions to Alfacell and the science behind onconase have been immeasurable," said David Sidransky, M.D...

Alfacell Reports Financial Results for Second Quarter of Fiscal 2008

... in the confirmatory Phase IIIb clinical trial for onconase (ranpirnase) in patients suffering from unresectab...rmaceutical, Inc. for the commercialization of onconase in the U.S. by Strativa, the branded product d...th BL&H Co. Ltd., for the commercialization of onconase in Korea, Taiwan and Hong Kong. Under the agr...
Other Tags
(Date:4/17/2014)... published today in PLOS Pathogens , children who ... common can mount an immune response to infection with ... bouts of high fever and illness and partially control ... findings may help researchers develop future interventions that prevent ... , Each year, approximately 200 million cases of malaria ...
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2
(Date:4/20/2014)... corn crop residue to make ethanol and other biofuels ... than gasoline, according to a study published today in ... findings by a University of Nebraska-Lincoln team of researchers ... to meet federal mandates to ramp up ethanol production ... the stalks, leaves and cobs in cornfields after harvest ...
(Date:4/18/2014)... while feeding a world population predicted to reach ... approach to conservation that considers human-altered landscapes such ... and the natural habitat that supports it might ... where at least three-quarters of the land surface ... is vulnerable to human-caused impacts such as climate ...
(Date:4/18/2014)... soon as they,re planted may be good news for a ... the wild, a plant whose seeds sprouted at the first ... just an insurance policy against late frosts or unexpected dry ... too: Plants whose seeds put off sprouting until conditions ... a team of researchers working at the National Evolutionary Synthesis ...
Breaking Biology News(10 mins):Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Plants with dormant seeds give rise to more species 2
Other Contents